Drug Database
Back to search

Japan· JP-2119408G1035

ミルリノン

A milrinone product containing ミルリノン, registered in Japan by 高田製薬, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.

On Japan’s NHI price listATC C01CE02

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedミルリノンATCC01CE02REGISTER NO.JP-2119408G1035PACKS LISTED0CHECKEDSeptember 25, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ミルリノンAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Milrinone is registered in 16 of 19 countries.

Countries holding a registration under ATC C01CE02 (milrinone), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 8 of them publish a price we can compare per daily dose
Search milrinone products by name

Milrinone · ATC C01CE02

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

MHLW / PMDA (Japan)
Active substance
ミルリノン
Manufacturer
高田製薬
Country
Japan (JP)
ATC code
C01CE02
ATC class
Milrinone
Defined daily dose
50 mg, P
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

5 interactions on record for milrinone.

Graded by severity as the source publishes them — 5 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check milrinone against other medicinesHow interaction checks work

Milrinone · interactions on record

5 records

  • 5 moderate

Most severe, free to view

  • ProcarbazineL01XB01moderate
  • AnagrelideL01XX35moderate
  • OzanimodL04AA38moderate
  • OzanimodL04AE02moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Milrinone in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All milrinone products

Authorised across Europe · EMA

The same active substance is authorised in 24 EEA countries. Names it is sold under:

  • Austria · Asicor, Milrinon Carino
  • Belgium · Corotrope
  • Bulgaria · Milrinon Makpharm
  • Czechia · Asicord, Corotrop
  • Germany · Corotrop, Milrinon Carinopharm
  • Denmark · Milnocor, Milrinon Stragen
  • Spain · Corotrope, Milrinone
  • Finland · Milnocor, Milrinon Stragen
  • France · Corotrope, Milrinone Carinopharm
  • United Kingdom (Northern Ireland) · Milrinone Carinopharm, Milrinone Macure Pharma Uk
  • Greece · Corotrope
  • Croatia · Milrinon Makpharm
  • Hungary · Corotrope, Unacor
  • Ireland · Milrinone Pinewood Laboratories
  • Luxembourg · Corotrope
  • Malta · Milrinone Tillomed
  • Netherlands · Milrinon Carinopharm, Milrinon Devrimed
  • Norway · Milnocor, Milrinon Stragen
  • Poland · Asicor, Corotrope
  • Portugal · Corotrope
  • Romania · Milrinone Zentiva, Unacor
  • Sweden · Corotrop, Milrinon Carinopharm
  • Slovenia · Milrinon Makpharm
  • Slovakia · Asicord, Corotrope Inj

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f54df5ad-5233-42ac-a551-ac76e3f5e024
GET /v1/drugs/f54df5ad-5233-42ac-a551-ac76e3f5e024?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "２２．５ｍｇ１５０ｍＬ１袋",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "2119408G1035",
  "category": "注射薬",
  "price_yen": 3368,
  "generic_name": "ミルリノン",
  "product_name_jp": null,
  "therapeutic_class": "2119",
  "transitional_expiry": null
}
API referenceMCP serverPlans

See everything about milrinone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console